Skip to main content

GlaxoSmithKline-gsk-logo

GlaxoSmithKline announced this morning that it will buy Tesaro, the maker of the ovarian cancer drug Zejula, for $5.1 billion in cash in a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock market.

{iframe}https://www.forbes.com/sites/matthewherper/2018/12/03/gsk-buys-tesaro-for-5-billion-in-dramatic-bet-on-cancer-genetics/amp/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.